Thursday, June 19th, 2025
Stock Profile: ABCL

AbCellera Biologics Inc. (ABCL)

Market: NASD | Currency: USD

Address: 2215 Yukon Street

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated Show more




📈 AbCellera Biologics Inc. Historical Chart






📊 Statistics





💰 Dividend History


No dividend history available.



📅 Earnings & EPS History for AbCellera Biologics Inc.


DateReported EPS
2026-02-25 (estimated upcoming)-
2025-11-03 (estimated upcoming)-
2025-11-02 (estimated upcoming)-
2025-08-04 (estimated upcoming)-
2025-08-03 (estimated upcoming)-
2025-05-08-
2025-05-05-
2025-05-04-
2025-02-27-0.11
2024-11-04-0.17
2024-08-06-0.13
2024-08-05-0.13
2024-05-07-0.14
2024-05-06-0.14
2024-02-20-0.17
2024-02-19-0.17
2023-11-02-0.1
2023-11-01-0.1
2023-08-03-0.11
2023-08-02-0.11
2023-05-04-0.14
2023-05-03-0.14
2023-02-21-0.1
2023-02-20-0.1
2022-11-080.08
2022-11-070.08
2022-08-09-0.02
2022-08-08-0.02
2022-05-100.54
2022-05-090.54
2022-02-240.19
2022-02-230.19
2021-11-09-0.08
2021-11-08-0.08
2021-08-12-0.01
2021-08-11-0.01
2021-05-130.37
2021-05-120.37
2021-03-290.44
2021-03-280.44
2020-12-14-
2020-12-13-




📰 Related News & Research


No related articles found for "abcellera biologics".